# 1 Improvement in quality of life and cognitive function in Post Covid

## 2 Syndrome after online occupational therapy: results from a

## 3 randomized controlled pilot study

- 4 Dominik Schröder, MPH<sup>1\*</sup>, Andrea Stölting<sup>2\*</sup>, Christina Müllenmeister, MSc OT<sup>1</sup>, Prof. Dr. med.
- 5 Georg M.N. Behrens<sup>2,8</sup>, Sandra Klawitter<sup>3,4</sup>, Prof. Dr. Frank Klawonn<sup>3,4</sup>, Aisha Cook<sup>5</sup>, Nadja
- 6 Wegner<sup>2</sup>, PD. Dr. med. Martin Wetzke<sup>6</sup>, Dr. rer. med. Tim Schmachtenberg<sup>1</sup>, M.A.<sup>1</sup>, Prof. Dr. med.
- 7 Alexandra Dopfer-Jablonka<sup>2,8,§</sup>, PD Dr. med. Frank Müller, MSc<sup>1,8§</sup>, Prof. Dr. med. Christine
- 8 Happle, PhD, MHBA<sup>3,7,9, §</sup>

9

10 11 12 13 14 15 16 17 18 19 20 21	<ul> <li><sup>1</sup>Department of General Practice, University Medicine Göttingen, Göttingen, Germany</li> <li><sup>2</sup>Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany</li> <li><sup>3</sup>Institute of Information Engineering, Ostfalia University of applied sciences, Wolfenbüttel, Germany</li> <li><sup>4</sup>Biostatistical Research Group, Helmholtz-Center for Infection Research, Braunschweig, Germany</li> <li><sup>5</sup>Tim-Cook Occupational Therapy, Hannover, Germany</li> <li><sup>6</sup>Department of Pediatric Allergology, Pneumology, and Neonatology, Hannover Medical School, Hannover, Germany</li> <li><sup>7</sup>German Center for Infection Research, RESIST, Hannover-Braunschweig, Germany</li> <li><sup>8</sup>Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids MI, USA</li> <li><sup>9</sup> German Center for Lung Research, DZL-BREATH, Hannover, Germany</li> <li><sup>*§</sup>contributed equally</li> </ul>
22	
23	
24	
25	
26	
27	Word Count: 2129
28	
29	
30	
31	Key words: occupational therapy, digital, Post Covid Syndrome, Long Covid, pilot
32	study, randomized controlled trial

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 33 Abstract

Background: Post-COVID-Syndrome (PCS) poses enormous clinical challenges. Occupational
 therapy (OT) is recommended in PCS, but structural validation of this concept is pending.

Methods: In an unblinded randomized pilot study (clinical trial # DRKS0026007), feasibility and effects of online OT in PCS were tested. Probands received structured online OT over 12 weeks either via interactive online treatment sessions (interactive group) or prerecorded videos (video group). 50% of probands received no online OT (control group). At week 0, 12, and 24, we analyzed study experience, health-related quality of life, and impairment in performance, participation, and cognitive functions.

42 Results: N=158 probands (mean age 38 yrs., 86% female) were included into the analyses. 83.3% of probands in the interactive versus 48.1% of probands in the video group described their study 43 44 experience as positive or very positive (p=0.001). After 12 weeks, all groups displayed significant 45 improvement in concentration, memory, and performance of daily tasks. After 24 weeks, significant improvement in concentration and memory were observed in control- and video-probands, and 46 social participation had improved after video-OT. However, only probands that had received 47 interactive online OT showed improvement of all measured endpoints including concentration, 48 49 memory, quality of life, and social participation.

50 **Conclusion:** We show that online OT is feasible and that interactive online OT is a promising 51 treatment strategy for affected patients. We present exploratory data on its efficacy and 52 describe variables that can be employed for further investigations in confirmatory trials.

## 54 Introduction

55 Approximately 3-10% of people with an acute SARS-COV-2 infection develop Post COVID-56 syndrome (PCS) with ongoing symptoms [1-3]. PCS affected people often experience severe 57 fatigue, trouble concentrating, and reduced quality of life and social participation [4-6]. Current 58 therapy guidelines for PCS mention occupational therapy (OT) as a treatment option [6], and case 59 reports describe success of OT in treating this novel condition [7]. However, clinical studies 50 confirming efficacy of OT in PCS are pending.

We sought to combine the concept of OT for PCS with the strategy of remote (digital) treatment delivery. Remote treatment strategies via digital communication have become more accepted since the COVID-19 pandemic [8]. As many PCS patients suffer from impaired mobility, digital treatment appears to be particularly appealing for this patient group [9]. Given the high prevalence of PCS, the scalability of digital therapy formats could enable efficient treatment for a high number of affected people.

Here, we tested the feasibility and efficacy of structured online OT for PCS in a randomized controlled, unpowered pilot study (German clinical trial registry #DRKS00026007 [10]). OT was based on a detailed manual tailored to the needs of PCS patients and delivered online, either by interactive sessions or as prerecorded videos. The aim of the intervention was to support affected people in developing coping strategies against major PCS symptoms such as fatigue and cognitive impairments and thus improve their quality of life and social participation.

## 74 Methods

### 75 Trial Design

This is a randomized controlled pilot study with two interventional groups receiving OT either via (I) interactive digital sessions (interactive group) or (II) prerecorded videos (video group). A control group (III) received no intervention (controls). Planned allocation ratio was 1:1:2 (I:II:III). Patients were evaluated upon study start (T1), after the 12-week treatment phase (T2) and 24 weeks after study start (T3). More study details are outlined in a study protocol [10]. No changes were made after trial commencement.

82

### 83 Participants and Recruitment

Following inclusion criteria were applied: [1] age  $\geq$  16 years, [2] persistent or new PCS 84 symptoms  $\geq$  4 weeks after SARS-CoV-2 infection (confirmed by PCR or rapid antigen testing), 85 [3] feeling of strong cognitive impairment and/or fatigue (concentration deficits and/or fatigue) 86 87  $\geq$  5/10 on a Likert scale, [4] access to a digital device, [5] consent to participate in the study. Recruitment was performed through an online study platform for persons affected by PCS 88 (DEFEAT Corona, German study registry number DRKS00026007 [11]). Interested patients 89 were asked to complete an online screening survey. PCS people meeting the inclusion criteria 90 91 were invited to participate by email. Prior to enrollment, individual consent talks were conducted which each interested eligible person and further study information was provided. Participants 92 declared written consent before enrollment. 93

94

### 95 Interventions

96 Participants in the interactive group received online OT by an experienced occupational 97 therapist twice weekly through interactive digital sessions. Probands in the video group were 98 provided with links for prerecorded OT videos for two weekly sessions. Outline and structure 99 of OT were based on a detailed manual tailored to the needs of PCS patients which was 100 identical in both interventional groups [10]. OT sessions consisted of guided exercises to

101 control typical PCS symptoms as well as customizable units to improve performance in 102 everyday occupations, social participation, and wellbeing. Participants in both groups also 103 received OT workbooks and were asked to apply contents into their everyday life 104 complementing the OT content of each therapy session regularly. Control participants received 105 no treatment.

1	0	6

### 107 Outcomes

108 Feasibility and acceptance of the treatment concept (primary endpoints) were analyzed by Likert scaled items (online questionnaire) and assessment of drop out rates in the different 109 study phases. Secondary endpoints were cognitive function and problems in everyday 110 occupations assessed by Neuro-QoL<sup>™</sup> v2.0 cognitive function short form [12], memory 111 112 function tested by the WIT-2 tool [13], and concentration deficits evaluated by the D2-R test [14]. Health-related quality of life was analyzed by the EQ-5D-3L index and EQ VAS [15]. 113 Social participation was evaluated by the Index for measuring participation restriction (IMET) 114 score [16], and occupational performance by the Canadian occupational performance measure 115 116 COPM based interviews [13].

117

#### 118 Sample size

As pilot study, the sample size was conceived pragmatically considering feasibility with regardto project funding

#### 121 Randomization

Probands were randomized into the three groups employing an urn model (ratio interactive/video/control group: 1/1/2) by a member of the study team not involved in the treatment intervention. After randomization, patients were tested for occupational problems using a structured interview according to the Canadian occupational performance measure (COPM [13]), again by an independent team member not involved in the intervention.

128

### 129 Statistical analyses

Sample characteristics where characterized using descriptive and bivariate statistics. Within 130 groups, changes between two time points were assessed by Wilcoxon signed rank testing. To 131 132 analyze longitudinal changes between groups, covariance analyses with repeated measurements were performed with baseline values, interventional arm, and time points as 133 covariables. Analyses of treatment effects were conducted according to the intention to treat 134 135 (ITT) principle [17], and missing values were imputed applying the last observation carried 136 forward (LOCF) strategy [18]. Adjusted differences between interventional versus control 137 groups at follow up visits are reported with confidence intervals (CI). P values were corrected 138 for multiple testing by Bonferroni Holm correction, and a p value p<0.05 was considered 139 statistically significant. Calculations were performed employing R (V4.2.3) with the packages 140 afex, eq5d, and gqplot2 [10, 19, 20].

141

### 142 Research Ethics

The study protocol was approved by responsible research ethics boards of all participating centers
(Hannover Medical School #9948\_BO\_K\_2021, University Medical Center Göttingen 15/8/22Ü).
The study was registered at the German Registry for Clinical Trials (trial number
DRKS00026007). Participants provided written informed consent prior to enrollment.

147 The project received funding through the German Federal Ministry for Education and Research148 (Grant number 01EP2103C).

149

### 151 Results

#### 152

153 Initially, n=163 PCS patients were recruited, but n=5 had to be excluded secondarily due to 154 failing the inclusion criteria (Fig. 1). In total, n=158 PCS patients were included into the final 155 analysis. 65.2% of participants completed the 12-week interventional or control period and 156 were available for evaluation and timepoint T2. 32.5% of probands in the interactive, and 157 53.8% of participants in the video group were lost to follow up at T2, as were 22.8% of control 158 probands. An additional 2.5% of participants were lost to follow up at timepoint T3.

From cases in the interventional arms with follow up data, data on subjective treatment effects was available for 98.7% of probands, and 72.2% provided information on their personal OT experience. Psychological testing was performed in 98.1%, and COPM in 88% of probands with follow up evaluation. Participant numbers for each study arm and timepoint are illustrated in Fig. 1.



164 165

Fig. 1: Flowchart illustrating study phases and proband numbers (PROM: patient reported outcome measures include
 NeuroQoL, EQ-5D, IMET)

The median age of participants was 38 years (IQR 30–45, range 16–67), and probands in the interventional groups were significantly younger than those in the control group (Table 1). The majority of participants (86.1%) were female, with more women in the interventional as in control groups. PCS participants in the interactive group presented with better memory performance (WIT-2) than those in control and video arms. Other characteristics that did not differ between the study groups are displayed in Table 1. Further information on sociodemographic characteristics is provided in supplementary Table 1.

	Total	Control	Video	Interactive	
	(n=158)	(n=79)	(n=39)	(n=40)	p-value
Age	38.0 (30.0 –	42.0 (31.5 –	35.0 (26.5 –	36.0 (29.0 –	0.038 <sup>1</sup>
(vears) <sup>a</sup>	45.0)	47.0)	41.0)	44.0)	
	Range 16 – 67	Range 16 – 61	Range 18 – 53	Range 16 – 67	
Female gender	136 (86.1)	51 (82.3)	24 (88.9)	17 (94.4)	0.025 <sup>2</sup>
SARS-CoV-2 infection until study start (weeks, n=5 missing)	41.1 (26.8 – 63.9)	43.1 (28.1 – 60.9)	38.0.7 (20.9 – 51.2)	42.6 (28.9 – 98.3)	0.251 <sup>1</sup>
Fatigue <sup>a</sup>	8.0 (7.0 –	8.0 (7.0 –	9.0 (7.0 – 10.0)	8.0 (7.0 – 9.0)	0.650 <sup>1</sup>
(Likert x/10)	9.0)	9.0)			
Trouble concentrating	8.0 (7.0 –	8.0 (7.0 –	8.0 (7.0 – 9.0)	7.0 (6.0 – 9.0)	0.757 <sup>1</sup>
(Likert x/10)ª	9.0)	9.0)			
d2-Rª	-1.0 (-1.6 – -	-1.1 (-1.0 – -	-0.9 (-1.60.2)	-0.8 (-1.5 – -	0.394 <sup>1</sup>
(n=3 missing)	0.2)	0.2)		0.1)	
WIT-2ª	0.1 (-0.6 –	-0.1 (-0.5 –	-0.1 (-1.0 – 0.3)	0.5 (-0.2 –	0.007 <sup>1</sup>
(n=3 missing)	0.5)	0.3)		0.9)	
EQ-5D-3L Index <sup>a</sup> (n=2 missing)	0.61 (0.39 – 0.75)	0.61 (0.39 – 0.75)	0.61 (0.38 – 0.75)	0.61 (0.484 – 0.75)	0.640 <sup>1</sup>
EQ VAS <sup>a</sup>	36.0 (30.0 -	37.0 (30.0 –	35.5 (30.3 –	36.0 (31.0 –	0.576 <sup>1</sup>
(n=2 missing)	51.0)	50.0)	49.0)	56.0)	
Neuro-QoL™ v2.0 Cognitive Function-Short Form <sup>a</sup> (n=3 missing)	33.0 (29.8 – 36.0)	34.0 (29.8 – 36.0)	33.0 (28.6 – 37.0)	32.0 (28.6 – 35.0)	0.833 <sup>1</sup>

IMET <sup>a</sup>	55.0 (41.3 –	53.5 (41.0 –	54.5 (44.8 –	59.5 (37.8 –	0.893 <sup>1</sup>
(n-6 missing)	66.0)	66.0)	66.0)	66.0)	
(II=0 IIII33IIIg)					
COPM – satisfaction	2.3 (1.5 –	2.3 (1.5 –	2.5 (1.3 – 3.0)	2.4 (1.5 – 3.3)	0.636 <sup>1</sup>
(n=19 missing)	3.0)	3.0)			
COPM – performance	3.0 (2.5 –	3.0 (2.5 –	3.0 (2.5 – 3.8)	3.0 (2.5 – 3.8)	0.816ª
(n=19 missing)	3.6)	3.5)			

177 178

Table 1: Proband characteristics at baseline

179 <sup>1</sup>Kruskal-Wallis testing; <sup>2</sup>Fisher-Freeman-Halton testing; <sup>a</sup>median (IQR); <sup>b</sup>number (proportion); \*comparison between control, video, and interactive group

181

190

182 To further analyze the acceptance of our concept, we asked PCS patients to rate their OT 183 experience during the 12-week intervention phase. In an online survey, they could rate their therapy perception between 0 (very negative) and 5 (very positive). Participants in the 184 185 interactive group evaluated their OT experience with a mean of 4.2 points (range 2–5, n=30), 186 and 83.3% rated the treatment as positive or very positive (Fig. 2). By contrast, probands in 187 the video group rated their OT experience with an average of 3.3/5 points (range 1–5, n=27), and only 48.1% described their experience as positive or very positive (Fig. 2, difference in 188 satisfaction p=0.001). 189



191 Fig. 2: Rating of study experience by participants in the two intervention groups

#### 192

193 Next, we performed an exploratory analysis of the intervention's efficacy in alleviating PCS 194 symptoms. In all groups, a significant improvement of concentration and memory, as well as 195 occupational performance was observed during the first 12 weeks of the study (Table 2). However, only in participants after interactive online OT, a significant improvement in health-196 related quality of life, social participation, and cognitive function as assessed by Neuro-QoL 197 occurred (Table 2). In comparison to controls, participants in the interactive group presented 198 199 with significantly stronger improvement in health-related quality of life (EQ-5D-3L index, mean 200 difference 0.11, 95% CI [0.02-0.19], p=0.01) and cognitive function (Neuro-QoL, mean 201 difference 2.36, 95% CI [0.27-4.46], p=0.022, Table 2).

202 24 weeks after the start of the study, all groups displayed significant improvement in 203 concentration and memory performance, and participants in the control and interactive groups 204 showed significant enhancement of social participation (Table 2). However, only PCS patients 205 in the interactive group presented with significant improvement of all measured end points 206 such as cognitive function, social participation, health-related quality of life, and occupational 207 performance (Table 2).

	T1 <sup>1</sup>	T2 <sup>1</sup>	T31	T1-T2 <sup>2</sup>	P T2-T3 <sup>2</sup>	P T1-T3 <sup>2</sup>
	(Baseline)	(12-Weeks)	(24-Weeks)	р	р	р
		Cont	rol			
d2-R	-1.10	-0.50	-0.30	<0.001	0.002	<0.001
(n=77)	(-1.90 – -0.20)	(-1.50 – 0.30)	(-1.20 – 0.30)			
WIT-2	-0.10	0.30	1.00	<0.001	<0.001	<0.001
(n=77)	(-0.50 – 0.30)	(-0.30 – 1.00)	(-0.10 – 1.60)			
EQ-5D-3L Index	0.613	0.613	0.649	0.912	0.092	0.419
(n=79)	(0.386 – 0.750)	(0.381 – 0.750)	(0.391 – 0.757)			
EQ VAS	37.00	36.00	35.00	0.590	0.590	0.590
(n=79)	(30.00 – 50.00)	(30.00 – 55.00)	(26.50 – 63.00)			

Neuro-QoL™ v2.	34.00	32.00	35.00	0.145	<0.001	0.074	
0 cogn. function- short form (n=79)	(29.80 – 36.00)	(28.60 – 37.00)	(29.80 – 38.90)				
IMET	53.50	53.00	52.00	0.125	0.125	0.021s	
(n=78)	(41.00 – 66.00)	(37.00 – 66.75)	(31.00 – 66.50)				
СОРМ	3.00	3.50	-	<0.001	-	-	
(n=66)	(2.50 – 3.50)	(2.54 – 4.50)					
COPM	2.25	2.50	-	<0.001	-	-	
(n=66)	(1.50 – 3.00)	(1.54 – 3.50)					
		Vide	20		I		
d2-R	-0.90	-0.60	-0.40	0.003	0.061	0.002	
(n=39)	(-1.60– -0.15)	(-1.35 – 0.30)	(-1.35 – 0.30)				
WIT-2	-0.10	0.10	0.30	0.002	0.495	0.001	
(n=39)	(-1.00 – 0.30)	(-0.30 – 1.15)	(-0.60 – 1.60)				
EQ-5D-3L Index	0.613 (	0.639	0.64	1.00	1.00	1.00	
(n=38)	0.38 – 0.75)	(0.381 – 0.750)	(0.39 – 0.77)				
EQ VAS	35.50	35.50	36.50	0.990	0.460	0.990	
(n=38)	(30.25 – 49.00)	(26.75 – 50.00)	(26.75 – 51.25)				
Neuro-QoL™ v2.	33.00	33.00	35.00	1.00	0.200	1.00	
short form (n=37)	(28.60 – 37.00)	(39.80 – 37.00)	(27.30 – 38.90)				
IMET	54.50	56.50	55.50	0.840	0.640	0.640	
(n=36)	(44.75 – 66.00)	(44.75 – 64.25)	(39.75 – <64.25)				
COPM	3.00	3.50	-	0.001	-	-	
(n=37)	(2.50 – 3.75)	(3.00 – 4.75)					
COPM	2.50	2.75	_	<0.001			
(n=37)	(1.25 – 3.00)	(2.25 – 4.75)					
	Interactive						
d2-R	-0.80	-0.10	-0.20	<0.001	0.002	<0.001	
(n=39)	(-1.50 – -0.10)	(-0.95 – 0.80)	(-0.95 – 0.80)				
WIT-2	0.50	1.00	1.30	<0.001	0.028	<0.001	
(n=39)	(-0.20 – 0.85)	(0.10 – 1.60)	(0.30 – 1.90)				
EQ-5D-3L Index	0.613	0.750	0.750	0.044	0.346	0.008	

(n=38)	(0.484 – 0.754)	(0.5 – 0.79	(0.57 – 0.79)			
EQ VAS	36.00	46.00	42.00	0.047	0.979	0.047
(n=38)	(31.00 – 56.00)	(34.00 – 65.00)	(32.50 – 65.00)			
Neuro-QoL™ v2.	32.00	34.00	34.00	0.026	0.132	0.004
0 coan. function-						
short form (n=37)	(28.60 – 35.00)	(30.90 – 37.45)	(30.35 – 39.40)			
IMET	59.50	48.50	49.00	0.023	0.836	0.012
(n=36)	(37.75 – 66.00)	(36.75 – 64.00)	(36.00 – 66.00)			
СОРМ	3.00	3.88	_	0.001	-	-
performance						
(n=36)	(2.50 – 3.75)	(2.94 – 4.81)				
(	. ,	. ,				
СОРМ	2.38	3.00	_	0.029	-	-
satisfaction						
(n=36)	(1.46 – 3.25)	(1.63 – 4.50)				

<sup>208</sup> 209 210

 Table 2: Effects of the study intervention on cognitive performance, quality of life, and occupational performance

 <sup>1</sup>Median (Q25-Q75); <sup>2</sup> Wilcoxon sign rank, Bonferroni Holm correction for multiple testing

### 213 Discussion

PCS is a growing global health problem which has been estimated to affect up to 11% of patients after SARS-CoV-2 infection [3]. In spite of high patient numbers worldwide and strong clinical need, effective treatment strategies are pending [21, 22].

Here, we present first results on the feasibility of online OT and explore the efficacy in PCS. The delivered parameters and data can be employed in larger randomized controlled clinical trials on novel PCS treatment strategies. Our data illustrates that online OT can be a valuable treatment approach in helping PCS patients better coping with their symptoms and restraints. We have shown that online delivered OT can significantly improve their cognitive function and quality of life.

223 Online delivered OT has several advantages especially for people with PCS: It can easily be 224 scaled meeting the current demand for treatment and may also be especially suitable for PCS people that struggle with impaired mobility or live in more remote places. In our study, online 225 226 provision of OT was used by participants of all ages, illustrating the wide range of PCS patients 227 that could be reached by such an approach. Around two thirds of PCS patients in the interactive 228 therapy group completed the 12-week treatment course in the interactive group as compared 229 to less than one half of those in the video group, and significantly more patients that were 230 treated interactively rated their OT experience as positive. This illustrates that personal 231 interaction significantly enhances acceptance of online treatment in PCS. Furthermore, PCS 232 patients after interactive OT displayed significant treatment benefits when compared to both video and control group. Their cognitive function showed statistically significantly improvement 233 234 and their health-related quality of life had increased by 0.11 points, a value clearly above the 235 threshold of 0.03 previously described to be clinically relevant [23]. The fact that secondary 236 outcomes such as memory and concentration capacity also improved in the control group could be explained by a natural amelioration of PCS symptoms over time, which has also been 237 observed by other researchers [24]. Importantly, only patients receiving interactive OT showed 238 significant improvement of all measured endpoints of cognitive function, occupational 239 240 problems, quality of life, and social participation.

Taken together, these findings advocate for high acceptance and therapeutic benefit of the interactive, person to person online OT in PCS patients.

243 Our study has several limitations. Firstly, due to it's novelty, a priori power calculations could 244 not be performed and the number of enrolled participants may have been too low to detect subtle treatment effects. Also, the inhomogeneity of groups upon study start with regard to age, 245 sex, and memory function may have impacted our results. The high rate of lost to follow up 246 participants needs to be addressed in future studies. Unfortunately, we were unable to 247 systematically assess reasons for study discontinuation in our cohort. The high proportion of 248 female study participants can be interpreted as another limitation of our work. It may be 249 250 explained by a higher rate of female PCS patients in general and the fact that women tend to 251 seek medical help earlier than men [25, 26]. Furthermore, central outcomes such as symptom severity were self-reported. As this feasibility study was performed in unblinded fashion, this 252 253 could have biased self-assessment. Finally, some of our test instruments such as WIT-2 and 254 d2r are not validated for repeated measurements, which could have led to improvement of scorings at the second test date. 255

In spite of these limitations, our study adds significant information to the field of PCS treatment. We provide detailed data on relevant clinical variables that can be employed in larger studies on PCS treatment in the future. Our exploratory analyses of treatment effects also support the notion that online OT is feasible in PCS and that interactive online OT may be a promising treatment strategy for affected patients.

As such we hope our data helps to pave the way for new, effective, and scalable treatment options in PCS.

263

## 265 **References**

266

Venkatesan P. NICE guideline on long COVID - The Lancet Respiratory Medicine. 2022. doi:
 doi:10.1016/S2213-2600(21)00031-X.

Chen Chen M. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Ajalysis
 and Systematic Review. 2022.

Kavanagh KT, Cormier LE, Pontus C, Bergman A, Webley W. Long COVID's Impact on Patients,
 Workers, & Society: A review. Medicine (Baltimore). 2024;103(12):e37502. Epub 2024/03/22. doi:
 10.1097/MD.00000000037502. PubMed PMID: 38518038; PubMed Central PMCID:
 PMCPMC10957027.

4. Koczulla AR, Ankermann T, Behrends U, Berlit P, Böing S, Brinkmann F, et al. S1-Leitlinie Post-COVID/Long-COVID. Pneumologie. 2021;75:869-900. doi: 10.1055/a-1551-9734.

5. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases. 2021. doi: 10.1016/s1473-3099(21)00703-9.

Koczulla AR, Ankermann T, Behrends U, Berlit P, Berner R, Boing S, et al. [German S1 Guideline
 Long-/Post-COVID]. Pneumologie. 2022;76(12):855-907. Epub 2022/12/09. doi: 10.1055/a-1946-3230.
 PubMed PMID: 36479679.

Wilcox J, jawilcox@usc.edu, Jamie Wilcox O, OTR/L, is Associate Professor, Clinical
 Occupational Therapy, Keck Medical Center of USC, Chan Division of Occupational Science and
 Occupational Therapy, University of Southern California, Los Angeles, Frank E, efrank@usa.edu, Emily
 Frank O, MS, OTR, is Assistant Professor and Manager of Simulation Education and Innovation
 Initiatives, University of St. Augustine for Health Sciences, Austin, TX. Occupational Therapy for the
 Long Haul of Post-COVID Syndrome: A Case Report. The American Journal of Occupational Therapy.
 2023;75(Supplement\_1). doi: 10.5014/ajot.2021.049223.

 Parry W, Fraser C, Crellin E, Hughes J, Vestesson E, Clarke GM. Continuity of care and consultation mode in general practice: a cross-sectional and longitudinal study using patient-level and practice-level data from before and during the COVID-19 pandemic in England. BMJ Open.
 2023;13(11):e075152. Epub 2023/11/16. doi: 10.1136/bmjopen-2023-075152. PubMed PMID: 37968008; PubMed Central PMCID: PMCPMC10660661.

Dahmen A, Keller FM, Derksen C, Rinn R, Becker P, Lippke S. Screening and assessment for
 post-acute COVID-19 syndrome (PACS), guidance by personal pilots and support with individual digital
 trainings within intersectoral care: a study protocol of a randomized controlled trial. BMC Infect Dis.
 2022;22(1):693. Epub 2022/08/16. doi: 10.1186/s12879-022-07584-z. PubMed PMID: 35971066;
 PubMed Central PMCID: PMCPMC9377288.

Singmann H BB, Westfall J, Aust F, Ben-Shachar M. \_afex: Analysis of Factorial Experiments\_. R
 package version 1.3-0. https://CRANR-projectorg/package=afex. 2023.

Mikuteit M, Heinemann S, Roder S, Niewolik J, Schroder D, Vahldiek K, et al. Long-term
Consequences of COVID-19 and the Pandemic: Protocol for a Web-Based, Longitudinal Observational
Study (DEFEAT). JMIR Res Protoc. 2022;11(10):e38718. Epub 2022/09/16. doi: 10.2196/38718.
PubMed PMID: 36108134; PubMed Central PMCID: PMCPMC9611102.

30612.healthmeasures.net.Neuro-QoL.https://wwwhealthmeasuresnet/explore-measurement-307systems/neuro-qol#:~:text=Neuro-

308 QoL%20TM%20%28Quality%20of%20Life%20in%20Neurological%20Disorders%29,by%20adults%20a
 309 nd%20children%20living%20with%20neurological%20conditions. 2022.

310 13. Martin Kersting KA, Adolf Otto Jäger. Wilde-Intelligenz-Test 2. Hofgreve\_1st\_edition. 2008.

Wollseiffen P, Ghadiri A, Scholz A, Struder HK, Herpers R, Peters T, et al. Short Bouts of
Intensive Exercise During the Workday Have a Positive Effect on Neuro-cognitive Performance. Stress
Health. 2016;32(5):514-23. Epub 2015/10/10. doi: 10.1002/smi.2654. PubMed PMID: 26449710.

15. Ozkeskin M, Ozden F, Karaman B, Ekmekci O, Yuceyar N. The comparison of fatigue, sleep quality, physical activity, quality of life, and psychological status in multiple sclerosis patients with or

316 without COVID-19. Mult Scler Relat Disord. 2021;55:103180. Epub 2021/08/06. doi: 10.1016/j.msard.2021.103180. PubMed PMID: 34352513; PubMed Central PMCID: PMCPMC8324500. 317 318 16. Schroder D, Mullenmeister C, Heinemann S, Hummers E, Klawonn F, Vahldiek K, et al. Social 319 participation during the COVID-19 pandemic in persons with a high risk for a severe course of COVID-320 19 - results of a longitudinal, multi-center observational study in Germany. Health Psychol Behav Med. 321 2023;11(1):2249534. Epub 2023/08/30. doi: 10.1080/21642850.2023.2249534. PubMed PMID: 322 37645515; PubMed Central PMCID: PMCPMC10461510.

17. T B. Intent-to-Treat Analysis Versus Per Protocol Analysis. Clinical trials. 2017:173-201.

324 18. Gupta SK. Intention-to-treat concept: A review. Perspect Clin Res. 2011;2(3):109-12. Epub
 325 2011/09/08. doi: 10.4103/2229-3485.83221. PubMed PMID: 21897887; PubMed Central PMCID:
 326 PMCPMC3159210.

327 19. Wickham H. ggplot2: Elegant Graphics for Data Analysis. . Springer-Verlag New York. 2016;ISBN
328 978-3-319-24277-4.

20. Morton F NJ. \_eq5d: Methods for Analysing 'EQ-5D' Data and Calculating 'EQ-5D' Index Scores\_. R package version 0.14.0. https://CRANR-projectorg/package=eq5d. 2023.

Xirchberger I, Meisinger C, Warm TD, Hyhlik-Durr A, Linseisen J, Gosslau Y. Post-COVID-19
Syndrome in Non-Hospitalized Individuals: Healthcare Situation 2 Years after SARS-CoV-2 Infection.
Viruses. 2023;15(6). Epub 2023/06/28. doi: 10.3390/v15061326. PubMed PMID: 37376625; PubMed
Central PMCID: PMCPMC10303962.

335 Schmachtenberg T, Konigs G, Dragaqina A, Roder S, Muller F, Mullenmeister C, et al. "There is 22. 336 no one who helps you with it": experiences of people with long COVID regarding medical care, 337 therapeutic measures, and barriers in the German healthcare system: results of a qualitative study 338 with four focus groups. BMC Health Serv Res. 2023;23(1):1160. Epub 2023/10/27. doi: 339 10.1186/s12913-023-10170-x. PubMed PMID: 37884993; PubMed Central PMCID: 340 PMCPMC10601213.

23. Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D
index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):221-33. Epub
2014/03/15. doi: 10.1586/14737167.2014.894462. PubMed PMID: 24625040.

Steinmetz A, Gross S, Lehnert K, Lucker P, Friedrich N, Nauck M, et al. Longitudinal Clinical
Features of Post-COVID-19 Patients-Symptoms, Fatigue and Physical Function at 3- and 6-Month
Follow-Up. J Clin Med. 2023;12(12). Epub 2023/06/28. doi: 10.3390/jcm12123966. PubMed PMID:
37373660; PubMed Central PMCID: PMCPMC10299126.

Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mule G, et al. Female gender is
associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect.
2022;28(4):611 e9- e16. Epub 2021/11/12. doi: 10.1016/j.cmi.2021.11.002. PubMed PMID: 34763058;
PubMed Central PMCID: PMCPMC8575536.

Sagar-Ouriaghli I, Godfrey E, Bridge L, Meade L, Brown JSL. Improving Mental Health Service
Utilization Among Men: A Systematic Review and Synthesis of Behavior Change Techniques Within
Interventions Targeting Help-Seeking. Am J Mens Health. 2019;13(3):1557988319857009. Epub
2019/06/12. doi: 10.1177/1557988319857009. PubMed PMID: 31184251; PubMed Central PMCID:
PMCPMC6560805.

357

#### Supplement

	T2 difference	T3 difference	P T2 <sup>2</sup>	P T3 <sup>2</sup>			
	(95% CI) <sup>1</sup>	(95% CI) <sup>1</sup>					
	d2-R <sup>3</sup>						
video vs. control	-0.07 (-0.42 – 0.28)	-0.14 (-0.57 – 0.30)	1.00	1.00			
interactive vs. control	0.08 (-0.28 – 0.43)	0.15 (-0.28 – 0.59)	0.783	0.783			
	WIT-2 <sup>3</sup>						
interactive vs. control	0.07 (-0.31 – 0.46)	-0.41 (-0.92 – 0.10)	1.00	1.00			
video vs. control	0.10 (-0.28 – 0.49)	-0.18 (-0.70 – 0.32)	0.158	0.746			
	EQ-5D-3L in	ldex <sup>3</sup>	I				
video vs. control	0.021 (-0.069 – 0.110)	0.006 (-0.108 – 0.095)	0.577	0.880			
interactive vs. control	0.106 (0.020 – 0.193)	0.065 (-0.033 – 0.163)	0.011	0.332			
	EQ VAS	3					
video vs. control	-1.21 (-8.47 – 6.05)	-4.47 (-13.27 – 4.32)	0.685	0.655			
interactive vs. control	4.09 (-3.89 – 12.07)	0.32 (-9.35 – 9.98)	0.449	0.936			
	Neuro-QoL <sup>™</sup> v2. 0 cognitive	function short form <sup>3</sup>					
video vs. control	0.48 (-1.63 – 2.58)	-1.25 (-4.26 – 1.77)	0.582	0.633			
interactive vs. control	2.36 (0.27 – 4.46)	0.80 (-2.20 – 3.81)	0.022	0.633			
	IMET <sup>4</sup>						
video vs. control	3.78 (-4.17 – 11.74)	3.63 (-5.67 – 12.93)	0.498	0.686			
interactive vs. control	-3.40 (-11.54 – 4.74)	-2.31 (-11.82 – 7.21)	0.498	0.686			
	COPM perform	mance					
video vs. control	0.13 (-0.50 – 0.75)	-	1.00	not assessed			
interactive vs. control	0.20 (-0.46 – 0.85)	-	1.00	not assessed			
COPM satisfaction							
video vs. control	0.30 (-0.45 – 1.05)	-	0.977	not assessed			
interactive vs. control	0.10 (-0.74 – 0.94)	-	1.00	not assessed			

363 364

Supplementary Table 1: Differences between study arms adjusted for baseline scores <sup>1</sup>differences and CI adjusted according to baseline values employing repeated measurement variance analyses, <sup>2</sup>Bonferroni Holm adjusted for multiple testing, <sup>3</sup>positive value: improvement, <sup>4</sup> negative value: improvement.